South Sefton CCG Governing Body 6 February 2020:  Item 20/10 Commissioning Policies

Appendix 1 – Criteria Based Clinical Treatment Policy : Suite 3 policies – Summary of Policy Changes

 

Policy name

Summary of policy changes

Policy Document

EIRA

i.    Botulinum Toxin A and B

The criteria for the use of this treatment now reflects the Pan Mersey Area Prescribing Committee (APC) positions and NICE Guidance. This refers to the use of Botox for hyperhidrosis and migraine. This update to match Pan Mersey means improved access to services.

 Policy for Botulinum Toxin A & B EIA Botox

ii.   Policy for Prostatism/Lower Urinary Symptoms in Men

At present there are criteria in place however commissioners feel a pathway to treatment would be more appropriate therefore this update incudes a pathway to treatment.

 Policy for Prostatistm/Lower Urinary tract symptoms in men EIA Prostatism

iii.  Secondary Care Administered Steroid Peripheral Joint Injections

There are a number of changes in criteria and clarification around setting in which to deliver injections.

 Policy for secondary care administered steroid peripheral joint injections EIA Joint injections

iv.  Continuous Glucose Monitoring

It has been requested that the policy makes more specific reference to the use of continuous glucose monitoring systems for pregnant women and children based on the latest clinical evidence.

 Policy for continuous glucose monitors EIA stage 2 CGM

v.   Insulin Pumps

Currently CCGs follow NICE TA151, however the draft policy for insulin pumps also makes provision for patients who have had a pancreatectomy and meet the criteria in NICE TA151 as well as patients with cystic fibrosis-related diabetes (CFRD)

 Policy for continuous sub-cutaneous insulin infusion (CSII) therapy  EIA stage 2 insulin pumps

vi.  Transanal Irrigation

Changes reflect NICE guidance and the use of electric pumps.

 Policy for transanal irrigation EIA TAI